Which has higher valuation and earnings, TLX or ABUS?

Telix Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.70 -$7.12M N/A N/A Arbutus Biopharma $14.08M 61.03 -$33.50M $0.83 5.24

Arbutus Biopharma (ABUS) Competitors

$4.35 +0.09 (+2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$4.34 0.00 (-0.11%)

As of 07:45 PM Eastern

Compare

ABUS vs. TLX, DNLI, RCUS, BEAM, and TNGX

Should you buy Arbutus Biopharma stock or one of its competitors? MarketBeat compares Arbutus Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arbutus Biopharma include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), Arcus Biosciences (RCUS), Beam Therapeutics (BEAM), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Telix Pharmaceuticals' score of 0.38 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Telix Pharmaceuticals	Neutral
Arbutus Biopharma	Positive

Telix Pharmaceuticals presently has a consensus target price of $21.13, indicating a potential upside of 140.88%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 14.94%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telix Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Telix Pharmaceuticals' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Arbutus Biopharma	83.95%	129.32%	112.24%

Telix Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.70	-$7.12M	N/A	N/A
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24

43.8% of Arbutus Biopharma shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Arbutus Biopharma beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to Denali Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Arbutus Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 14.94%. Denali Therapeutics has a consensus price target of $34.25, indicating a potential upside of 74.21%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Arbutus Biopharma has a net margin of 83.95% compared to Denali Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Denali Therapeutics	N/A	-52.20%	-43.86%

Arbutus Biopharma has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arbutus Biopharma has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Denali Therapeutics	$330.53M	9.44	-$512.54M	-$2.88	N/A

In the previous week, Denali Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Denali Therapeutics and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Denali Therapeutics' score of 1.26 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Denali Therapeutics	Positive

Summary

Arbutus Biopharma beats Denali Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Arcus Biosciences?

Arbutus Biopharma (NASDAQ:ABUS) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Arbutus Biopharma has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Arcus Biosciences' net margin of -156.36%. Arbutus Biopharma's return on equity of 129.32% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Arbutus Biopharma currently has a consensus target price of $5.00, indicating a potential upside of 14.94%. Arcus Biosciences has a consensus target price of $33.89, indicating a potential upside of 41.90%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Arbutus Biopharma has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Arcus Biosciences	$247M	12.16	-$353M	-$3.18	N/A

In the previous week, Arcus Biosciences had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 3 mentions for Arcus Biosciences and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Arcus Biosciences' score of 0.09 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Arcus Biosciences	Neutral

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Arbutus Biopharma beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Beam Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Beam Therapeutics had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Beam Therapeutics and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Beam Therapeutics' score of 0.81 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Beam Therapeutics	Positive

Arbutus Biopharma has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Beam Therapeutics	$139.74M	21.76	-$79.99M	-$0.68	N/A

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arbutus Biopharma currently has a consensus target price of $5.00, indicating a potential upside of 14.94%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 58.49%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Arbutus Biopharma has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Beam Therapeutics' net margin of -39.66%. Arbutus Biopharma's return on equity of 129.32% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Summary

Arbutus Biopharma beats Beam Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Tango Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Tango Therapeutics had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 3 mentions for Tango Therapeutics and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Tango Therapeutics' score of 0.93 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Tango Therapeutics	Positive

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arbutus Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 14.94%. Tango Therapeutics has a consensus price target of $32.27, indicating a potential upside of 50.32%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Arbutus Biopharma has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Tango Therapeutics	$62.38M	49.79	-$101.59M	-$0.83	N/A

Arbutus Biopharma has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Tango Therapeutics' net margin of -151.15%. Arbutus Biopharma's return on equity of 129.32% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Summary

Arbutus Biopharma beats Tango Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABUS vs. The Competition

Export

Metric	Arbutus Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$841.51M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	5.24	17.78	22.39	24.18
Price / Sales	61.03	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	10.88	6.63	9.84	6.72
Net Income	-$33.50M	$24.20M	$3.57B	$337.19M
7 Day Performance	-6.25%	-3.24%	-1.16%	0.48%
1 Month Performance	0.69%	0.53%	3.85%	5.07%
1 Year Performance	26.09%	47.24%	27.40%	34.25%

Arbutus Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABUS Arbutus Biopharma	2.2157 of 5 stars	$4.35 +2.1%	$5.00 +14.9%	+26.8%	$841.51M	$14.08M	5.24	90	Positive News
TLX Telix Pharmaceuticals	4.4826 of 5 stars	$9.47 flat	$21.13 +123.1%	-45.5%	$3.21B	$803.79M	N/A	1,184	Gap Up High Trading Volume
DNLI Denali Therapeutics	3.7209 of 5 stars	$18.64 flat	$34.25 +83.7%	+38.6%	$2.96B	$330.53M	N/A	430	Positive News
RCUS Arcus Biosciences	2.4512 of 5 stars	$23.48 +0.2%	$33.89 +44.4%	+165.3%	$2.95B	$247M	N/A	500
BEAM Beam Therapeutics	2.1129 of 5 stars	$28.64 flat	$46.83 +63.5%	+78.9%	$2.95B	$139.74M	N/A	510

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABUS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Competitors

ABUS vs. TLX, DNLI, RCUS, BEAM, and TNGX

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Summary

How does Arbutus Biopharma compare to Denali Therapeutics?

Summary

How does Arbutus Biopharma compare to Arcus Biosciences?

Summary

How does Arbutus Biopharma compare to Beam Therapeutics?

Summary

How does Arbutus Biopharma compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Competitors

ABUS vs. TLX, DNLI, RCUS, BEAM, and TNGX

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Does the media prefer TLX or ABUS?

Do analysts rate TLX or ABUS?

Which has more risk and volatility, TLX or ABUS?

Is TLX or ABUS more profitable?

Which has higher valuation and earnings, TLX or ABUS?

Do insiders & institutionals hold more shares of TLX or ABUS?

Summary

How does Arbutus Biopharma compare to Denali Therapeutics?

Do analysts recommend ABUS or DNLI?

Is ABUS or DNLI more profitable?

Which has more risk and volatility, ABUS or DNLI?

Do insiders and institutionals believe in ABUS or DNLI?

Which has better earnings and valuation, ABUS or DNLI?

Does the media favor ABUS or DNLI?

Summary

How does Arbutus Biopharma compare to Arcus Biosciences?

Which has more risk & volatility, ABUS or RCUS?

Is ABUS or RCUS more profitable?

Do analysts recommend ABUS or RCUS?

Which has higher valuation and earnings, ABUS or RCUS?

Does the media favor ABUS or RCUS?

Do institutionals & insiders believe in ABUS or RCUS?

Summary

How does Arbutus Biopharma compare to Beam Therapeutics?

Does the media favor ABUS or BEAM?

Which has preferable valuation and earnings, ABUS or BEAM?

Do insiders and institutionals believe in ABUS or BEAM?

Do analysts rate ABUS or BEAM?

Which has more risk & volatility, ABUS or BEAM?

Is ABUS or BEAM more profitable?

Summary

How does Arbutus Biopharma compare to Tango Therapeutics?

Does the media favor ABUS or TNGX?

Do insiders & institutionals believe in ABUS or TNGX?

Do analysts rate ABUS or TNGX?

Which has stronger earnings & valuation, ABUS or TNGX?

Which has more risk and volatility, ABUS or TNGX?

Is ABUS or TNGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools